We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Is recurrent hepatitis C worse with living donors?
Current Opinion in Organ Transplantation 2009 June
PURPOSE OF REVIEW: Early reports suggested that hepatitis C virus (HCV) infection recurred with greater severity in recipients of living donor liver transplantation (LDLT) compared with recipients of deceased donor liver transplantation (DDLT). Consequently, there has been uncertainty in the transplant community as to whether to encourage use of live donors for patients undergoing transplantation for HCV. This review will present the current data regarding whether recurrent HCV is worse with living donors.
RECENT FINDINGS: More recently published studies have not corroborated the results of earlier studies showing inferior graft and patient survival in recipients of LDLT. The Adult-to-Adult Live Donor Liver Transplant Cohort Study showed that patient and graft survival in HCV-positive LDLT recipients was similar to that in DDLT recipients once centers had experience with LDLT. Additionally, studies using protocol liver biopsies to assess disease severity found no significant difference in the rate of fibrosis progression between recipients of LDLT and DDLT.
SUMMARY: There is no difference in graft survival or fibrosis progression between recipients of LDLT compared with DDLT with follow-up periods up to 5 years. Available data support the use of LDLT as an additional donor source for these patients.
RECENT FINDINGS: More recently published studies have not corroborated the results of earlier studies showing inferior graft and patient survival in recipients of LDLT. The Adult-to-Adult Live Donor Liver Transplant Cohort Study showed that patient and graft survival in HCV-positive LDLT recipients was similar to that in DDLT recipients once centers had experience with LDLT. Additionally, studies using protocol liver biopsies to assess disease severity found no significant difference in the rate of fibrosis progression between recipients of LDLT and DDLT.
SUMMARY: There is no difference in graft survival or fibrosis progression between recipients of LDLT compared with DDLT with follow-up periods up to 5 years. Available data support the use of LDLT as an additional donor source for these patients.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app